ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Overview
The Anumana ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm is a software as a medical device (SaMD) designed to assist clinicians in identifying adult patients who may be at risk for Cardiac Amyloidosis (CA) using a standard 12-lead electrocardiogram (ECG).
- What it does:This AI-enabled algorithm analyzes ECG waveforms to detect patterns associated with CA that may not be apparent through human interpretation. It is intended to aid in earlier detection of CA in adults being evaluated for signs or symptoms consistent with the condition, including those with unexplained heart failure, nephrotic syndrome, peripheral neuropathy, arrhythmias, or aortic stenosis.
- Who it is for:The tool is relevant for various specialties and care settings where patients are evaluated for cardiac symptoms, particularly those with comorbidities associated with CA. This includes cardiologists, primary care physicians, and other clinicians in hospital or outpatient settings.
- How it fits a clinical or practice workflow:The algorithm integrates into existing clinical workflows by utilizing standard 12-lead ECGs that are routinely obtained in practice, without requiring additional testing. It is not intended as a standalone diagnostic tool but rather to support clinicians in identifying patients who may benefit from further evaluation for CA.
- Notable capabilities:The ECG-AI CA algorithm was developed at Mayo Clinic and validated in a multi-center study.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-driven analysis of standard 12-lead ECGs
- Detects cardiac disease signals invisible to the human eye
- Integrates with existing clinical workflows and EHRs
- Aids in earlier detection of Cardiac Amyloidosis
- Software as a Medical Device (SaMD)
- Clinically validated with extensive evidence base
- Supports clinical decision-making at the point of care
- Eligible for reimbursement
Use Cases
- Early identification of cardiac amyloidosis in adults being evaluated for consistent signs or symptoms
- Screening patients with conditions commonly associated with cardiac amyloidosis (e.g., unexplained heart failure, nephrotic syndrome, peripheral neuropathy, arrhythmias, aortic stenosis)
- Supporting clinicians in recognizing suspicion of cardiac amyloidosis from routine ECGs
- Guiding further clinical evaluation for at-risk patients
What Physicians Need to Know
This AI-powered ECG algorithm serves as a valuable screening tool to flag patients at risk for cardiac amyloidosis, especially those with non-specific symptoms or comorbidities like unexplained heart failure, nephrotic syndrome, peripheral neuropathy, arrhythmias, or aortic stenosis. A positive result warrants further clinical evaluation, but a negative result in a high-risk patient should not rule out additional investigation. It's crucial to integrate this tool with clinical judgment and existing guidelines, as it is not a stand-alone diagnostic device. The ability to detect CA earlier, even before advanced imaging, can significantly impact patient outcomes by enabling timely interventions.
The ECG-AI Cardiac Amyloidosis 12-Lead Algorithm is designed as a software-as-a-medical-device (SaMD) that integrates into existing clinical workflows by analyzing standard 12-lead ECG data already gathered in practice, without requiring additional testing. It is built on a secure, clinically validated infrastructure to support seamless integration across diverse healthcare systems. The algorithm was developed in collaboration with Mayo Clinic and has been validated in large, independent, multi-center studies across various U.S. health systems. Anumana is actively pursuing regulatory approval for this algorithm in the USA, Europe, and Japan.
Details
| Category | Cardiology AI, Clinical Decision Support & Reference |
| Pricing | Unknown |
| Deployment | Integrated with existing ECG management systems and EHR environments |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Hospital Medicine, Internal Medicine |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Videos
Product demos, reviews, and walkthroughs for ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm.







